AI That Learns the Rules: Symbolic Neural Generators Design New Drug Candidates

Artificial intelligence has become an increasingly powerful tool in the search for new medicines, but a persistent problem has haunted the field: neural networks that invent molecules are remarkably creative yet notoriously unreliable. They can propose chemical structures that look plausible on paper but violate basic principles of chemistry or pharmacology, forcing medicinal chemists to sift through mountains of unusable suggestions. A new study published in the journal Machine Learning offers a fresh answer to this dilemma by marrying the pattern-recognition strengths of large language models with the logical rigor of symbolic reasoning, producing a hybrid framework the researchers call Symbolic Neural Generation, or SNG.

The work, led by Ashwin Srinivasan of BITS Pilani in Goa, together with Tirtharaj Dash, A. Baskar, Michael Bain, Sanjay Kumar Dey, and Mainak Banerjee, addresses a class of hybrid neurosymbolic models that remains relatively under-explored. Rather than letting a neural generator run free and filtering its output afterward, SNG inverts the relationship. A symbolic learner first examines logical specifications of what counts as feasible data, sometimes from as few as a single example. That specification then constrains the conditional information supplied to a neural generator, which is required to reject any candidate instance that violates the symbolic description. The result is a pair consisting of a symbolic description of feasible instances and a set of newly generated instances that provably satisfy it.

Technically, the framework rests on a formal semantics built from partially ordered sets. The researchers construct what they describe as base and fibre posets, combined into an overall partial order that characterizes the space of hybrid systems. The symbolic component in their implementation draws on a restricted form of Inductive Logic Programming, a family of techniques dating back decades that learns logical rules from examples and background knowledge. The neural component is a large language model prompted to produce candidate molecules as SMILES strings, the standard text encoding of molecular structure. Each candidate is checked against the learned logical specification before it is accepted, ensuring that every generated molecule conforms to the constraints the symbolic learner has inferred.

To score candidate hypotheses, the system employs a Bayesian heuristic originally developed in the ILP literature, which balances the prior probability of a hypothesis against how well it explains positive and negative examples. The search over hypotheses proceeds through nested hyper-rectangles defined over molecular factors such as predicted binding affinity, molecular weight, and synthetic accessibility score. Sampling within these rectangles uses a Latin Hypercube approach, and each successive experiment narrows the constraints, producing hypotheses that are logically entailed by their predecessors. The authors prove formal properties about this procedure, including guarantees that the generated sets remain within the feasible extension of the learned hypothesis.

The application that gives the work its urgency is early-stage drug design, specifically the discovery of lead compounds, the validated starting points from which medicinal chemists develop actual drug candidates. The team evaluated their SNG implementation on benchmark protein targets whose biology is well understood, including JAK2 and DRD2, alongside dopamine beta-hydroxylase, or DBH, a comparatively poorly studied enzyme implicated in cardiovascular disease. Binding affinities of generated molecules were estimated computationally using the GNINA molecular docking program, which predicts how strongly a small molecule will lodge itself in the binding pocket of a protein target.

The results are striking. On the benchmark problems, where drug targets are well characterized, SNG performance was statistically comparable to state-of-the-art methods for molecular generation. More intriguing still were the exploratory experiments on DBH, a target for which little domain knowledge exists in the literature. Molecules generated by the system for this target exhibited predicted binding affinities on par with leading clinical candidates. Because the symbolic learner had to infer target-specific constraints from just five known inhibitors, the achievement suggests the framework can operate productively even in the data-sparse regimes that characterize most real drug discovery projects, where high-throughput screening data is expensive and incomplete.

The choice of neural generator turned out to matter in unexpected ways. The researchers compared OpenAI’s GPT-4o, Anthropic’s Claude 3.5 Sonnet, and a small 87-million-parameter GPT-2 model trained on roughly 480 million molecules from the ZINC chemical database. The general-purpose models performed well on heavily studied targets like JAK2 and DRD2, presumably because their vast training corpora include relevant biochemical literature. But the chemistry-specialized Molecule-GPT2 outperformed them on DBH, the lesser-studied target, where knowledge had to be extracted from the inhibitor molecules themselves rather than recalled from pretraining. Notably, the entire study cost only around ten US dollars in API fees per commercial model, underscoring that the framework is not wedded to any particular language model and could accommodate open-source alternatives.

Perhaps the most persuasive endorsement came from human experts. A structural biologist and a synthetic organic chemist reviewed the system’s outputs and found the symbolic specifications genuinely useful as preliminary filters for triaging candidates. Several of the generated molecules were judged viable for synthesis and wet-laboratory testing, a meaningful threshold for any computational design method. The experts’ assessments also highlighted a practical advantage of the neurosymbolic approach: because the system produces an explicit logical description of what makes a molecule feasible, chemists can inspect, critique, and refine the criteria rather than treating the generator as an inscrutable black box.

The authors are careful to situate their contribution within the broader neurosymbolic movement, sometimes called the third wave of neurosymbolic AI, which seeks to combine learning and reasoning rather than choosing between them. They acknowledge that the categorization of systems into purely symbolic or purely neural roles is necessarily a simplification, since induction typically requires deduction and complex reasoning involves trial-and-error learning. They also conjecture that the symbolic learner at the heart of SNG may yield more reliable hypotheses and reduce the number of experiments a laboratory robot would need to conduct in automated discovery loops. Extensions to wider classes of hybrid systems, including those where the neural component plays the primary role, are outlined in the paper’s appendices.

The implications extend well beyond one enzyme or one pharmaceutical project. By demonstrating that logical specifications learned from tiny datasets can steer a generative language model toward chemically meaningful and synthetically plausible outputs, the study offers a template for constrained generation in any scientific domain where correctness matters, from materials design to protein engineering. The researchers have released their code and data openly through a public repository, and the framework’s modest computational demands mean that laboratories without access to frontier-scale models could adopt the approach immediately. As generative AI moves from producing text to proposing tangible scientific artifacts, frameworks like SNG suggest that the path forward lies not in bigger models alone, but in models that know the rules they must obey.

Subject of Research: Hybrid neurosymbolic AI systems that integrate symbolic learning with neural generation for discovering lead molecules in early-stage drug design

Article Title: Symbolic Neural Generation with Applications to Lead Discovery in Drug Design

Article References: Srinivasan, A., Dash, T., Baskar, A., Bain, M., Dey, S. K., & Banerjee, M. (2026). Symbolic Neural Generation with Applications to Lead Discovery in Drug Design. Machine Learning, 115(9), Article 210. https://doi.org/10.1007/s10994-026-07136-5

Image Credits: AI Generated

DOI: 10.1007/s10994-026-07136-5

Keywords: neurosymbolic AI, drug discovery, large language models, inductive logic programming, molecular generation, lead discovery, machine learning, binding affinity, symbolic reasoning, drug design, GPT-4o, dopamine beta-hydroxylase